408 results
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
to the date that this representation is made.
(j) Litigation. Except as set forth on Schedule 3.1(j), there is no action, suit, inquiry, notice … terminated, (c) for the settlement of any outstanding litigation, or (d) in violation of FCPA or OFAC regulations.
4.8 Indemnification of Purchasers
424B5
SEEL
Seelos Therapeutics Inc
20 May 24
Prospectus supplement for primary offering
4:16pm
adverse development with respect to the FDA’s review of that NDA;
significant lawsuits, including patent or stockholder litigation;
inability … competitors;
disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection
8-K
EX-99.1
SEEL
Seelos Therapeutics Inc
14 May 24
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
11:45am
of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the reverse stock
8-K
SEEL
Seelos Therapeutics Inc
3 May 24
Entry into a Material Definitive Agreement
5:06pm
the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict
8-K
vj6eo
19 Mar 24
Other Events
4:05pm
8-K
EX-99.2
jtuxpe8jemjb44nzd4t1
19 Mar 24
Other Events
4:05pm
8-K
EX-99.1
1qb46n
19 Mar 24
Other Events
4:05pm
8-K
EX-10.2
hpd9jad6j likx5wt0cg
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
e6oe angog2z680
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
qfcllt85lp4dcf82660r
30 Jan 24
Prospectus supplement for primary offering
6:05am
8-K
EX-99.1
u5ofclhvx 3qn
22 Jan 24
Other Events
8:05am
DEFA14A
eiauml
2 Jan 24
Additional proxy soliciting materials
8:10am
DEFA14A
5c2awtenvleo
22 Dec 23
Additional proxy soliciting materials
8:10am
8-K
EX-99.1
1ulmcwc0zwrgzhvosbcv
1 Dec 23
Seelos Therapeutics Announces Closing of Public Offering
4:08pm
8-K
hx51 s0fmq3m
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-1.1
d1lbfo y86
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-99.1
kgb8kx7xbo
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm